Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intravenous GP-1-531 adenosine regulating agent: Began Phase I trial in the U.K. of the intravenous form owned by ARAM; the oral form, owned by GNSA, willl be t

Gensia Inc. (GNSA), San Diego

Read the full 56 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE